Global Onychomycosis Market Size By Product (Antifungal Medications, Non-Pharmacological Products), By Treatment (Pharmacological, Non-Pharmacological), By Geographic Scope And Forecast

Onychomycosis Market Size And Forecast

Onychomycosis Market size was valued at USD 4.2 Billion in 2022 and is projected to reach USD 6.45 Billion by 2030, growing at a CAGR of 5.5% from 2023 to 2030.

The increasing number of diabetes patients, an aging population, and rising health care expenditures per capita are all factors that are supporting the Onychomycosis Market. The Onychomycosis Market has seen growth as a result of rising health consciousness and higher levels of discretionary money. The Global Onychomycosis Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Onychomycosis Market Definition

Onychomycosis is a fungal infection of the nails that can cause discoloration, thickness, and separation of the nail from the nail bed. This condition is called onychomycosis. This condition is known as tinea unguium. Onychomycosis can present itself in a number of different forms, the most common of which are distal subungual onychomycosis, white superficial onychomycosis (WSO), proximal subungual onychomycosis, and candidal onychomycosis. These conditions are brought on by a wide variety of fungi, the most common of which are dermatophytes, Candida (yeasts), and molds that are not dermatophytes. Dermatophytes are the fungi most responsible for onychomycosis in temperate western countries. People living in tropical and subtropical regions with hot and humid climates are more likely to be affected by other infections, such as candida and non-dermatophyte molds.

Onychomycosis is an infection caused by fungi that can affect either the fingernails or the toenails. This infection may cause major problems, including deformity, discomfort, and pain, and it may also lead to serious complications. Onychomycosis is characterized by brittle, ragged, crumbly nails as well as a putrid odor. Additional symptoms include distortion in the shape of the nails. Onychomycosis can be caused by a compromised immune system, diabetes, circulation issues, excessive sweating, decreased blood flow, psoriasis, and ongoing contact with fungi. The symptoms of this condition are listed below. The expanding global population and the rising incidence of onychomycosis are both factors that are expected to create several potential for growth in the Onychomycosis Market. There are a variety of therapeutic options available for onychomycosis, including medicines, photodynamic therapy, and laser therapy.

There is a possibility that the increasing research and development activities for novel medications and treatments for onychomycosis will present the Onychomycosis Market with significant prospects for expansion. Onychomycosis can have a negative impact on a patient’s ability to function emotionally, socially, and professionally. Onychomycosis can further lead to social stigmatization and isolation from social groups. In spite of the fact that socioeconomic challenges and health concerns related to other diseases are given priority, the advent of improved systemic treatment regimens over the course of the past two decades has helped in the increase of people receiving treatment for this condition. An increase in the number of people being diagnosed with nail infections has led to a rise in knowledge regarding the issue, which in turn has fueled the increased desire for treatments that are successful.

Global Onychomycosis Market Overview

The growing number of diabetes patients, an aging population, and rising health care expenditures per capita are all variables that are expected to have a significant positive impact on the Onychomycosis Market. The Onychomycosis Market in the United States is Benefiting from Increasing Health Awareness and Increasing Disposable Income. On the other hand, factors such as a lack of information and the potential negative effects of medications are examples of restrictions that might have an impact on the expansion of the Onychomycosis Market. It is believed that the COVID-19 outbreak will have only a short-term effect on the Onychomycosis Market, despite the fact that it has rearranged the priorities and spending of the national healthcare system.

Less frequent patient visits point to a lower rate of treatment adoption, which is having a negative impact on the market. In addition to this, one other element that brings about a decline in sales is patients’ decreased visits to medical institutions in an effort to avoid cross-contamination. In addition, onychomycosis, in comparison to other chronic diseases, are typically not given a great deal of importance in the medical community. As a result of the disease’s less severe manifestations, the market has witnessed even lower levels of sales activity during the covid-19. It has been demonstrated that oral treatment can act as a growth accelerator for the Onychomycosis Market. The preference of a significant portion of the population for the oral consumption of medications such as Ciclodan, ciclopirox, Jublia, efinaconazole, Penlac, and others is one of the primary factors contributing to the expansion of the Onychomycosis Market.

The main causes of the age-related increase in onychomycosis include a number of factors such as prolonged exposure to pathogenic fungi, repeated nail trauma, diabetes, suboptimal immune function, prolonged contact with pathogenic fungi, inactivity, or the inability to cut the toenails or maintain foot care. In order to increase their position in the market, domestic companies are turning to a variety of techniques, such as research and development, mergers and acquisitions, and the introduction of new products. Oral consumption is becoming increasingly popular in the industry as a result of the efficacy of these products and the convenience they offer in terms of treatment. As a result, there is a possibility that the Onychomycosis Market would experience healthy expansion due to rising medicine usage.

The Onychomycosis Market is poised to benefit from the multiple prospects for expansion brought about by the numerous initiatives that are done by the government bodies in numerous countries to modernize the healthcare infrastructure. In addition, an increase in awareness efforts regarding onychomycosis from both the government and non-governmental groups has been shown to be a development driver for the Onychomycosis Market. The burgeoning industry of medical tourism across a wide variety of places is contributing to the significantly increased growth rate.

Global Onychomycosis Market Segmentation Analysis

The Global Onychomycosis Market is Segmented on the basis of Product, Treatment, And Geography.

Onychomycosis Market, By Product

• Antifungal Medications
• Non-Pharmacological Products
• Nail Care Products
• Others

Based on Product, the market is segmented into Antifungal Medications, Non-Pharmacological Products, Nail Care Products, and Others. The Nail Care Products segment will dominate the market. An increase in the prevalence of topical nail lacquers can be seen as a trend in the market when compared with antifungal drugs. The tablet segment may grow because of the factor that the government is trying to switch to generic drugs.

Onychomycosis Market, By Treatment

• Pharmacological
• Non-Pharmacological
• Others

Based on Treatment, the market is segmented into Pharmacological, Non-Pharmacological, and Others. For the treatment of fungal nail infections, both topical and oral medicines are available. The major goal of therapy, as evidenced by microscopy and culture, is to completely eliminate the organism from the body. The oral medications griseofulvin, terbinafine, itraconazole, and ketoconazole are the most usually used for the treatment of onychomycosis. The downsides of oral antifungal medicines, such as terbinafine, are that they need a longer treatment time and have greater side effects than topical antifungal drugs.

Onychomycosis Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, the Global Onychomycosis Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Due to high drug prices, an increasing senior population, and an increasing frequency of onychomycosis and diabetes patient populations in this region, it is anticipated that the onychomycosis treatment market in North America will hold a significant part of the global market. Onychomycosis is more common in older people for a variety of reasons, including repeated nail trauma, poor peripheral circulation, diabetes, suboptimal immune function, longer exposure to pathogenic fungi, inactivity, or the inability to cut toenails or maintain good foot care. The risk of onychomycosis increases with age. In order to improve their standing in the market, local companies are turning to a number of different tactics, including research and development, mergers and acquisitions, and the introduction of new products.

Key Players

The “Global Onychomycosis Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Medimetriks Pharmaceuticals Inc.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In April 2021, Alembic Pharmaceuticals Limited (Alembic) made the announcement that it has gained tentative approval from the US Food and Drug Administration for its joint venture Aleor Dermaceuticals Limited (Aleor).
• Lupin Limited was granted permission by the Food and Drug Administration of the United States in February 2021 for its Tavaborole Topical Solution, which was designed to treat onychomycosis.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.